The American Society of Clinical Oncology meeting just concluded and Lung Cancer Considered has a summary of the meeting, with a unique lung cancer focus. Tune in as host Stephen Liu and guests Dr. Alfredo Addeo and Dr. Heather Wakelee discuss key findings from ASCO 2021.

In this edition of Lung Cancer Considered, host Dr. Narjust Duma discusses the use of neoadjuvant immunotherapy, through a multidisciplinary lens, with guests Dr. Leah Backhus and Dr. Patrick Forde.

In this episode of Lung Cancer Considered, Dr. Stephen Liu sits down with guest Dr. Harpreet Singh from the FDA to discuss the agency’s oncology drug approval process. The interview also covers how new drug approvals are handled in other countries

In this episode of Lung Cancer Considered, guests Dr. Kristin A. Higgins and Dr. Antonio Calles discuss the case of a 42-year-old woman who presents to the emergency room with right shoulder pain and a dry cough that has worsened over the previous two months. A CT scan reveals she has a four-centimeter mass in her right lobe. Her PDL-1 is 1-2 percent. She has a limited history of smoking but no co-morbidities but she has lost 10 pounds since she was first seen in the emergency room.

This new episode of Lung Cancer Considered features a discussion of the seminal trial KEYNOTE 001 and how it impacted research and clinical care for patients with lung cancer. This podcast is noteworthy because, in addition to including researcher Dr. Eddie Garon, it also features the unique perspective from Cary Parton, a patient who participated in this trial.

This episode of Lung Cancer Considered covers recent promising results with new targeted agents for NSCLC harboring a KRAS G12C mutation. Thoracic oncologists have long thought this condition was undruggable, but results presented at WCLC 2020 from the CodeBreak 100 trial provide hope that new therapies will be more readily available.

The latest edition of Lung Cancer Considered features a discussion on a virtual tumor board in mesothelioma, involving a case with a 68-year-old male, with 30 pack years smoking history who presents to the ER due to a worsening shortness of breath at rest and with exertion, unresectable mesothelioma with chest wall invasion and pleural effusion thickening with enlarged mediastinal lymph nodes and right chest wall invasion. Thoracentesis revealed a serosanguineous fluid (removed 1.1 l) with improvement of the respiratory symptoms. Cytology was negative for malignancy. Thoracoscopy is done to obtain pleural biopsies. Listen as guests Dr. Aaron Mansfield and Dr. Anna Nowak discuss the case and offer treatment options.

In this episode of Lung Cancer Considered, Dr. Sai-Hong Ignatius Ou shares his career growth and experience participating and leading breakthrough clinical trials on therapies to treat ALK positive patients with lung cancer. Dr. Ou discusses a pivotal moment at the beginning of his career when he visited the Pfizer campus in California to learn about their effort to develop a phase 1 trial examining MET amplifications and MET mutations. The visit helped spur him to become more involved in lung cancer research.

This edition of Lung Cancer Considered discusses important science presented at the recently completed European Lung Cancer Congress, the multidisciplinary lung cancer meeting co-organized by ESMO and IASLC. Dr. Enriqueta Felip and Dr. Fabrice Barlesi share their interpretation of the following clinical trials presented at ELCC:

Adagrasib (MRTX849) -- phase Ib expansion and phase II monotherapy cohorts

CheckMate 9LA -- randomized 719 patients with EGFR/ALK wild type NSCLC to standard chemotherapy or 2 cycles of chemotherapy with nivolumab and Ipilimumab

KEYNOTE-407-- randomized squamous NSCLC to carboplatin with choice of nab/ paclitaxel or paclitaxel, and either pembrolizumab or placebo

AMG 757-- BiTE: bispecific T-cell engager targeting DLL3 and engaging CD3

CAMEL-sq trial-- phase III randomized trial in patients with advanced squamous NSCLC

The latest edition of Lung Cancer Considered features a discussion on a virtual tumor board case involving squamous cell lung cancer. Our guests are Dr. Enriqueta Felip, who is a professor of medicine and section in chief, Medical Oncology and Department Director of Thoracic Oncology at the Vall d’Hebron University Hospital in Barcelona. Joining Dr. Felip is Dr. Paul Paik, an associate attending physician and clinical director, of the Thoracic Oncology Service Department of Medicine Memorial Sloan Kettering Cancer Center in New York.